Almatica Patent-Cliff Exposure & CMS Drug Spending Portfolio

Almatica (US): 9 reconciled FDA prescription therapies (1.3% 2025 to 2030 cliff risk), $97.6M 2024 CMS Part D & Medicaid spend, and 3 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies9
2025 to 2030 Patent-Cliff Revenue Exposure1.3%
Primary Portfolio LOE Date2028-01-01
2024 CMS Total Public Spend$97.6M
2024 Medicare Part D Spend$77.3M
2024 Medicaid Spend$20.3M
California HCAI SB 17 Filings3 WAC filings (max 56.6% 2-yr change)